None listed
Conditions
Brief summary
The overall aim of the current study is to examine the brain correlates of emotion recognition in patients with HD using a double-blind placebo controlled intranasal oxytocin design and two MRI techniques involving fMRI and diffusion tensor imaging (DTI).
Interventions
Two acute (24 IU) treatment conditions including; a) intranasal placebo, and b) intranasal oxytocin (Syntocinon, Novartis, Switzerland). The two treatment conditions will be separated by a minimum of 1 week (washout period). The nasal sprays will be administered 50 mins prior to the functional magnetic resonance (fMR) protocol. The fMRI protocol will involve showing participants a brief task involving pictures of human faces expressing different emotions.
Sponsors
Monash Biomedical Imaging
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Eligibility
Sex/Gender
Male
Age
25 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
For Healthy controls: Males; Right-handed; between the ages of 25-55 years; non-smoker and no drug/alcohol abuse; medication free; and no metal objects present in body (or which can't be removed or which is not MRI safe). For Huntington's disease (HD): As above plus a diagnosis of the disease is required.
Exclusion criteria
Clinically significant medical or neurological condition (other than HD for the patients), significant head injury (or loss of consciousness from longer than 5 mins), presence of ferrous-containing metals within the body, inability to tolerate small enclosed spaces without anxiety.
Outcome results
None listed